EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension

Shengyuan Yu iD, Hui Su, Hebo Wang, Meiyun Zhang, Steve Barash, Glenn Chen, Gloria Yiu, Juline Bryson, Yoel Kessler, Yael Carmeli Schwartz, Zipi Roth-Ben Arie, Michal Benedek-Segal und 1 weitere

Cephalalgia · 2026-08 · 46 (8)

DOI: 10.1177/03331024261462833 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, online erschienen am 19.08.2026. Verfasst von Shengyuan Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Chinese PLA General Hospital, First Medical Center, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Migraine Disorders. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Teva Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Fremanezumab is approved for migraine prevention in Europe, the United States (US), Japan, South Korea, and several other countries; however, there are no data available on fremanezumab as a migraine preventive treatment in a Chinese population. This study evaluated the efficacy and safety of fremanezumab in Chinese adults with migraine.

Methods

This randomized, multicenter, Phase 3 trial consisted of a 4-week screening period, a 12-week double-blind period (DBP), and a 12-week open-label extension (OLE). Chinese adults with episodic and chronic migraine were randomized 1:1:2 to receive fremanezumab monthly (225 mg), fremanezumab quarterly (675 mg), or matched monthly placebo during the DBP. During the OLE, all participants received fremanezumab monthly (225 mg). The primary endpoint was mean change from baseline in monthly migraine days (MMD) during the DBP. Secondary endpoints included mean change from baseline in migraine days during the first 4 weeks of treatment and in monthly number of days with acute headache medication use during the DBP. Similar endpoints were assessed during the OLE. Safety assessments included, but were not limited to, adverse event (AE) reporting.

Results

In total, 365/454 screened participants were randomized to fremanezumab (n = 182 [monthly, n = 91; quarterly, n = 91]) or placebo (n = 183). Significantly greater changes from baseline in MMD were observed with fremanezumab versus placebo during the DBP (−4.6 vs −2.8; p < 0.0001) and in mean migraine days during the first 4 weeks of treatment (−4.5 vs −2.2; p < 0.0001). The mean change from baseline in days of acute headache medication use during the DBP was −3.0 with fremanezumab and −1.1 for placebo ( p < 0.0001). During the OLE, the mean change from baseline in MMD was −6.8 and −7.2 for those assigned to fremanezumab and placebo, respectively, during the DBP. The percentage of participants with any AE was similar between fremanezumab and placebo groups during the DBP (47% vs 43%); serious AEs were infrequent (fremanezumab, 1%; placebo,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalMigraine DisordersAdultFemaleHumansMaleMiddle AgedChinaDouble-Blind MethodTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

Chinese adultscalcitonin gene-related peptidefremanezumabmigraine preventionrandomized controlled trial

Substanzen

Antibodies, Monoclonalfremanezumab

Autor:innen und Institutionen

  • Department of Neurology, Chinese PLA General Hospital, First Medical Center, Beijing, China.
  • Department of Neurology, Hebei General Hospital, Shijiazhuang, China.
  • Department of Neurology, Tianjin Union Medical Center, Tianjin, China.
  • Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
  • Teva Pharmaceutical Information Consulting (Shanghai) Co., Ltd, Beijing, China.
  • Teva Pharmaceutical Industries Ltd, Tel Aviv, Israel.

ORCID-Profile: Shengyuan Yu, Xiaoping Ning

Förderung

  • Teva Pharmaceuticals

Zitieren

APA

Yu, S., Su, H., Wang, H., Zhang, M., Barash, S., Chen, G., Yiu, G., Bryson, J., Kessler, Y., Carmeli Schwartz, Y., Roth-Ben Arie, Z., Benedek-Segal, M., & Ning, X. (2026). Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension. Cephalalgia, 46(8). https://doi.org/10.1177/03331024261462833

Vancouver

Yu S, Su H, Wang H, Zhang M, Barash S, Chen G, et al. Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension. Cephalalgia. 2026;46(8). doi:10.1177/03331024261462833

BibTeX
@article{Yu2026,
  author = {Yu, Shengyuan and Su, Hui and Wang, Hebo and Zhang, Meiyun and Barash, Steve and Chen, Glenn and Yiu, Gloria and Bryson, Juline and Kessler, Yoel and Carmeli Schwartz, Yael and Roth-Ben Arie, Zipi and Benedek-Segal, Michal and Ning, Xiaoping},
  title = {Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension},
  journal = {Cephalalgia},
  year = {2026},
  volume = {46},
  number = {8},
  doi = {10.1177/03331024261462833}
}
Kostenlos starten →